

Draft Guidance on Fingolimod

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Fingolimod

Form/Route: Capsule/Oral

Recommended studies: 2 studies

1. **Type of study:** Fasting

Design: Single-dose, two-way crossover *in-vivo*

Strength: 0.5 mg x 3 capsules (1.5 mg dose)

Subjects: Healthy males and non-pregnant females, general population.

Additional Comments: Fingolimod has a long terminal elimination half-life ($t_{1/2}$). Please ensure adequate washout periods between treatments in the crossover studies. You may also consider using a parallel study design. Please refer to the Amiodarone HCl Tablets Draft Guidance for additional information regarding long half-life drugs.

2. **Type of study:** Fed

Design: Single-dose, two-way crossover *in-vivo*

Strength: 0.5 mg x 3 capsules (1.5 mg dose)

Subjects: Healthy males and non-pregnant females, general population.

Additional Comments: Please see comment above.

Please refer to the Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analytes to measure (in appropriate biological fluid): Fingolimod and its active metabolite, fingolimod-phosphate in whole blood

Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and C_{max}.

Bioequivalence based on (90% CI): Fingolimod

Waiver request of *in-vivo* testing: Not Applicable

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.